Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL1313560 | 0.95 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ALMNAHRH2 | |
| SCHEMBL10243152 | 0.85 | MEN1 (0.62) | ALDH1A1MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL13150170 | 0.82 | KDM4E (0.60) | ALDH1A1MEN1KMT2ALMNAGRIN2B | |
| SCHEMBL15688093 | 0.81 | TMEM97 (0.60) | ALDH1A1MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL1314311 | 0.79 | MEN1 (0.71) | ALDH1A1MEN1KMT2ALMNAGRIN2B | |
| SCHEMBL1312424 | 0.79 | MAPT (0.46) | ALDH1A1MEN1KMT2ALMNATMEM97 | |
| SCHEMBL1312780 | 0.79 | FNTA (0.49) | ALDH1A1MEN1KMT2ALMNAGRIN2B | |
| Hydrochloric Acid SCHEMBL1313138 | 0.78 | MEN1 (0.69) | ALDH1A1MEN1KMT2ALMNAGRIN2B | |
| Hydrochloric Acid SCHEMBL1312266 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ALMNATMEM97 | |
| SCHEMBL1313183 | 0.78 | NPSR1 (0.57) | ALDH1A1MEN1KMT2ALMNAHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | claimed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313096-A1 | NEW COMPOUNDS V | AstraZeneca AB (Publ) (SE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2009147211-A1 | NEW COMPOUNDS V | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275637-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | ALDH1A1 1875/4885MEN1 3508/4885KMT2A 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.